Friday, 16 October 2026European Markets

KLEPIERRE And PATRIMOINE ET COMM Have A High Dividend Yield And Return On Equity In The Real Estate Sector.

Loading stream...

(vianews) - klepierre (li.pa) is among this list of stock assets with the highest dividend rate and return on equity on the real estate sector.

financial asset price forward dividend yield return on equity
klepierre (li.pa) €24.00 7.32% 1.7%
patrimoine et comm (pat.pa) €20.00 6.1% 6.3%

several euronext companies pay out dividends to its shareholders. the dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.

1. klepierre (li.pa)

7.32% forward dividend yield and 1.7% return on equity

klépierre sa is the european leader in shopping malls, combining property development and asset management skills. the company's portfolio is valued at €19.3 billion at december 31, 2023, and comprises large shopping centers in more than 10 countries in continental europe which together host hundreds of millions of visitors per year. klépierre sa holds a controlling stake in steen & strøm (56.1%), scandinavia's number one shopping center owner and manager. klépierre sa is a french reit (siic) listed on euronext paris and is included in the cac next 20 and epra euro zone indexes. it is also included in ethical indexes, such as euronext cac 40 esg, euronext cac sbt 1.5, msci europe esg leaders, ftse4good, euronext vigeo europe 120, and features in cdp's “a-list”. these distinctions underscore the group's commitment to a proactive sustainable development policy and its global leadership in the fight against climate change.

earnings per share

as for profitability, klepierre has a trailing twelve months eps of €0.6.

pe ratio

klepierre has a trailing twelve months price to earnings ratio of 40. meaning, the purchaser of the share is investing €40 for every euro of annual earnings.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 1.7%.

more news about klepierre.

2. patrimoine et comm (pat.pa)

6.1% forward dividend yield and 6.3% return on equity

patrimoine et commerce sa, a real estate company, engages in the acquisition, development, and operation of commercial real estate properties in france. the company operates a portfolio of 31 real estate assets covering a total area of 129,280 square meters located in high-attraction areas in the suburbs or centers of medium-sized cities. its property portfolio includes shopping malls, supermarkets, shops, and business parks. the company is based in boulogne-billancourt, france.

earnings per share

as for profitability, patrimoine et comm has a trailing twelve months eps of €1.91.

pe ratio

patrimoine et comm has a trailing twelve months price to earnings ratio of 10.47. meaning, the purchaser of the share is investing €10.47 for every euro of annual earnings.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 6.3%.

more news about patrimoine et comm.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com